Nuvaira has developed the dNerva® Lung Denervation System, a pioneering catheter-based technology designed to treat overactive airway nerves in patients with Chronic Obstructive Pulmonary Disease (COPD). This system facilitates a one-time outpatient procedure known as Targeted Lung Denervation (TLD), which involves the use of a specialized catheter to perform circumferential ablation in the main bronchi of each lung. By disrupting the neural input to the lungs, the dNerva system aims to reduce the clinical consequences associated with neural hyperactivity, such as chronic airway inflammation and exacerbations. The procedure is designed to be non-surgical, allowing patients to return home the same day, and has shown promising results in stabilizing lung function and improving quality of life over time.

Clinical studies have demonstrated the safety and efficacy of the dNerva system, with significant reductions in the risk of severe COPD exacerbations observed over two and three-year follow-ups. The technology operates by reducing the release of acetylcholine, a neurotransmitter that contributes to heightened neural activity in the lungs, thereby promoting a state of "low alert" in the pulmonary system. This innovative approach not only addresses the underlying pathophysiology of COPD but also offers a potential alternative for patients who do not respond adequately to traditional anticholinergic drug therapies. The dNerva system comprises the Nuvaira Console, which manages the ablation process, and the dNerva Catheter, designed for compatibility with various bronchoscopes, ensuring a streamlined and effective treatment experience.

United States

Nuvaira was established in 2008 to address unmet clinical needs in the treatment of overactive airway nerves, a common disease feature of both COPD. The company offers innovative COPD therapies to help preserve patient lung health with a catheter-based system used to treat overactive airways.

Nuvaira

Company Details